Editorial: Are multiple biomarker testing strategies ready for prime time in heart failure?

Circulation: Heart Failure

Volumn 2, Issue 5, 2009, Pages 387-388

  Lee, Douglas S ^a,c   Tu, Jack V ^a,b,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b Schulich Heart Centre   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Biomarkers; Heart failure

Indexed keywords

ALBUMIN; ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; D DIMER; FIBRINOGEN; HOMOCYSTEINE; N TERMINAL PROATRIAL NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; TROPONIN T; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; DISEASE SURVEILLANCE; DYSPNEA; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; MORTALITY; PHYSICAL EXAMINATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SCREENING TEST; SYSTOLIC DYSFUNCTION; BLOOD; COMMUNITY CARE; METABOLISM; NOTE; PREDICTION AND FORECASTING; RISK ASSESSMENT; TIME; UPREGULATION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; COMMUNITY HEALTH SERVICES; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; TIME FACTORS; TROPONIN T; UP-REGULATION;

EID: 70350447504     PISSN: 19413289     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.109.898429     Document Type: Editorial

References (16)

1. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. J Am Med As Soc. 2002;288:1252-1259.
2. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
3. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 2005;330:625.
4. You JJ, Austin PC, Alter DA, Ko DT, Tu JV. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J. 2007;153:462-470.
5. Peacock WF, De MT, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008;358:2117-2126.
6. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol. 2005;20:201-210.
7. Dunlay SM, Gerber Y, Weston SA, Killian JM, Redfield MM, Roger VL. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail. 2009;2:393-400.
8. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H, Yoon SI, Suter T, Osterhues HH, Schieber MM, Hilti P, Schindler R, Brunner-La Rocca HP. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. J Am Med As Soc. 2009;301:383-392.
9. Schneider HG, Lam L, Lokuge A, Krum H, Naughton MT, De Villiers SP, Bystrzycki A, Eccleston D, Federman J, Flannery G, Cameron P. B-type natriuretic peptide testing, clinical outcomes, and health services use in emergency department patients with dyspnea: a randomized trial. Ann Intern Med. 2009;150:365-371.
10. Singer AJ, Birkhahn RH, Guss D, Chandra A, Miller CD, Tiffany B, Levy P, Dunne R, Bastani A, Thode HC, Hollander JE. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II) : A randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail. 2009;2:287-293.
11. Lee DS, Austin PC, Rouleau JL, Liu PP, Naimark D, Tu JV. Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. J Am Med As Soc. 2003;290:2581-2587.
12. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631-2639.
13. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, Engstrom G, Persson M, Smith JG, Magnusson M, Christensson A, Struck J, Morgenthaler NG, Bergmann A, Pencina MJ, Wang TJ. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. J Am Med As Soc. 2009;302:49-57.
14. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119:3070-3077.
15. Lee DS, Austin PC, Stukel TA, Alter DA, Chong A, Parker JD, Tu JV. "Dose-dependent" impact of recurrent cardiac events on mortality in patients with heart failure. Am J Med. 2009;122:162-169.
16. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154:260-266.